Citius Oncology announces a $18M fundraise to support the launch of LYMPHIR, a cancer immunotherapy. The offering is backed by a healthcare-focused investor.
PUBLIC · CTORDec 09, 2025
Amount Raised
$18 Million
Round Type
Funding Round
United StatesBiotechnologyHealth CareMedicalTherapeuticsPharmaceuticalBiopharma
Investors
Single Healthcare Focused Investor
Description
Citius Oncology, Inc. has entered into a definitive agreement for a registered direct offering of 1,284,404 shares at $1.09 per share. Additionally, the company will issue warrants for the purchase of shares as part of a concurrent private placement. The funds raised will strengthen its cash position and support the commercial launch of LYMPHIR
Company Information
Company
Citius Oncology
Location
United States
About
Citius Oncology, Inc. is a Delaware-based clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of cancer. The company specializes in the development of novel cancer treatments, including targeted therapies and immunotherapies, designed to improve the effectiveness and safety of cancer care. Citius Oncology operates primarily in the United States and is listed on The Nasdaq Capital Market under the ticker symbol CTOR. The company's strategic focus includes advancing its pipeline of therapies through clinical trials, positioning itself to address unmet medical needs in oncology, and catering to the growing demand for effective cancer treatments.
Fundz sees it the moment Citius Oncology raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
United StatesBiotechnologyHealth CareMedicalTherapeuticsPharmaceuticalBiopharma